title: Prophylaxis of congenital toxoplasmosis. Effects of spiramycin on placental infection.
abstract: The results of parasitological investigation of the placenta for toxoplasma in 223 cases with documented congenital toxoplasmosis were analysed according to whether the mother had been treated, or not, with spiramycin during pregnancy. The investigation was negative in 10-11% of the cases when the mother had not been treated or had been inadequately treated; in 25% of the cases with a treatment of 3 g spiramycin day; and in 50% with spiramycin plus the combination of pyrimethamine with sulphonamide. This series is compared with a previous group of 321 women whose placental investigation was negative in 50% of untreated cases and 81% of treated women. The treatment categories are not directly comparable, because it is not possible to have a randomly assigned 'no treatment' group, for ethical reasons. Correlation between spiramycin treatment and negative results of mouse inoculation of placental material suggests that spiramycin might decrease the risk of materno-fetal transmission of toxoplasma by reducing the severity and duration of toxoplasmic placentitis. Current use of spiramycin in infected pregnant women is recommended because of its activity and lack of side effects. The dosage must not be lower than 3 g/day. Additional pyrimethamine plus sulphonamide should be restricted to selected cases with fetal abnormality diagnosed during pregnancy. Some data on pharmacology of spiramycin in mothers, placentas and fetuses are reviewed. They suggest that monitoring of maternal serum antibody titres for a dosage more adapted to individual cases may be desirable.
authors.affiliation: Laboratoire de Sérologie Néonatale et de Recherche sur la Toxoplasmose, Institute de Puériculture de Paris, France.
authors.forename: J
authors.initials: J
authors.lastname: Couvreur
authors.forename: G
authors.initials: G
authors.lastname: Desmonts
authors.forename: P
authors.initials: P
authors.lastname: Thulliez
mesh_terms: D005260:Female; D006801:Humans; D010922:Placenta Diseases / Q000188:drug therapy*; D011247:Pregnancy; D014123:Toxoplasmosis / Q000635:transmission; D014125:Toxoplasmosis, Congenital / Q000469:parasitology / Q000517:prevention & control*